Jump Financial, LLC Liquidia Corp Transaction History

Jump Financial, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$11.35 - $16.73 $1.27 Million - $1.87 Million	-111,736 Reduced 69.56%	48,905 $721,000
Q4 2023 Oct 21, 2024	BUY	$5.77 - $12.19 $841,958 - $1.78 Million	145,920 Added 991.24%	160,641 $1.93 Million
Q4 2023 Feb 07, 2024	BUY	$5.77 - $12.19 $926,898 - $1.96 Million	160,641 New	160,641 $1.93 Million
Q2 2023 Oct 21, 2024	BUY	$6.63 - $9.9 $97,600 - $145,737	14,721 New	14,721 $115,000
Q2 2023 Aug 07, 2023	BUY	$6.63 - $9.9 $97,600 - $145,737	14,721 New	14,721 $115,000
Q2 2022 Aug 09, 2022	SELL	$3.37 - $7.55 $152,987 - $342,747	-45,397 Reduced 80.9%	10,716 $46,000
Q1 2022 May 12, 2022	BUY	$5.14 - $7.38 $86,418 - $124,079	16,813 Added 42.78%	56,113 $403,000
Q4 2021 Feb 10, 2022	BUY	$2.71 - $5.17 $106,503 - $203,181	39,300 New	39,300 $191,000
Q3 2021 Nov 12, 2021	SELL	$2.28 - $2.95 $44,512 - $57,592	-19,523 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$2.51 - $3.11 $49,002 - $60,716	19,523 New	19,523 $56,000
Q1 2021 May 17, 2021	SELL	$2.42 - $3.6 $33,880 - $50,400	-14,000 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$2.6 - $5.79 $36,400 - $81,060	14,000 New	14,000 $41,000

162

36M

1.79M

380K

Ticker LQDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,362,300
Market Cap $709M
Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.